Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by Pugsrock2on Jan 04, 2018 5:40pm

155 Views

Post# 27284583

RE:RE:NEWS OUT

so sounds like they are going to be out of money and doing a very dilutive financing at a very low share price. I guess the short position talked about in a previous post is significant as someone will want to depress the stock price to get more shares for less.

Bullboard Posts

Calibre discovers significant gold in Newfoundland